| Literature DB >> 22615751 |
Michelle H M M T van Velthoven1, Lorainne Tudor Car, Josip Car, Rifat Atun.
Abstract
BACKGROUND: Low cost, effective interventions are needed to deal with the major global burden of HIV/AIDS. Telephone consultation offers the potential to improve health of people living with HIV/AIDS cost-effectively and to reduce the burden on affected people and health systems. The aim of this systematic review was to assess the effectiveness of telephone consultation for HIV/AIDS care.Entities:
Mesh:
Year: 2012 PMID: 22615751 PMCID: PMC3355163 DOI: 10.1371/journal.pone.0036105
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Search strategy MEDLINE.
| Number | Search terms |
|
| phone* |
|
| telephon* |
|
| telefon* |
|
| telephone intervention |
|
| call |
|
| calls |
|
| calling |
|
| telemedicine |
|
| teleconsult* |
|
| telecounsel* |
|
| Telephone[MeSH] |
|
| Hotlines[MeSH] |
|
| Cellular phone[MeSH] |
|
| #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 |
|
| HIV Infections[MeSH] |
|
| HIV[MeSH] |
|
| hiv[tw] |
|
| hiv-1*[tw] |
|
| hiv-2*[tw] |
|
| hiv1[tw] |
|
| hiv2[tw] |
|
| hiv infect*[tw] |
|
| human immunodeficiency virus[tw] |
|
| human immunedeficiency virus[tw] |
|
| human immune-deficiency virus[tw] |
|
| ((human immun*) AND(deficiency virus[tw])) |
|
| “Acquired Immunodeficiency Syndrome”[MeSH] |
|
| acquired immunodeficiency syndrome[tw] |
|
| acquired immunedeficiency syndrome[tw] |
|
| acquired immuno-deficiency syndrome[tw] |
|
| acquired immune-deficiency syndrome[tw] |
|
| ((acquired immun*) AND (deficiency syndrome[tw])) |
|
| #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 |
|
| randomized controlled trial [pt] |
|
| controlled clinical trial [pt] |
|
| randomized [tiab] |
|
| placebo [tiab] |
|
| drug therapy [sh] |
|
| randomly [tiab] |
|
| trial [tiab] |
|
| groups [tiab] |
|
| #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 |
|
| animals [mh] NOT humans [mh] |
|
| #42 NOT #43 |
|
|
|
Overview of HIV testing and HIV prevention studies.
| Study | Setting | Participants | Intervention (I) | Control (C) | Outcomes (O) | Results |
|
| ||||||
| Tsu 2002 | Portland, Oregon, US. | Homeless and high-risk youth requesting HIV testing. |
| Usual care group, required to receive test results face-to-face at the clinic. | O.1) Proportion of participants receiving HIV test results. | O.1) I: 57.6%, C: 37.1%. Significant difference between groups in favour of I (odds ratio = 2.264, 95% confidence interval [1.445–3.547] P<0.001). |
|
| ||||||
| Rotheram-Borus 2004 | AIDS clinics, community-based sites and solicitation in newspapers, conferences, etc. in Los Angeles, San Francisco, and New York, US. | Substance using HIV-positive youth. |
| C.1.In person intervention group | O.1) Sexual risk behaviour. O.2) Substance use. O.3) Adherence to antiretroviral treatment regimen. O.4) Number of missed appointments. O.5) Brief Symptom Inventory score (emotional distress). | O.1) Proportion of protected acts with HIV-negative partners. I. Decrease from 75% at baseline to 65% at 15 months. C1. Increase from 53% at baseline to 73% at 15 months. Significant difference between I and C1 (P<0.01). O.2) O.3) O.4) O.5) No significant differences between I and C1 or C2. |
Abbreviations: US = United States, N = number of participants.
Overview of the mental health studies.
| Study | Setting | Participants | Intervention (I) | Control (C) | Outcomes (O) | Results |
| Eaton1995 | Veteran Administration Hospital Centre HIV/AIDS program, US. | MaleHIV-positiveveterans. |
| Group onlyreceiving theoutcome assessments. | O.1) Rate of change in the General Severity Index of the Brief Symptom Inventory (psychosocial symptoms). O.2) General Severity Index mean change score. | O.1) No significant difference between I and C (P = 0.2). O.2) I: 5.89 (SD = 4.97), C: 0.93 (SD = 5.82). Significant difference between I and C (P<0.05). |
| Heckman2007 | 27 AIDS service organisationsin 13 statesof the US. | People livingwith HIVin ruralareas. |
| Usual carewith access toall services. | O.1) BDI. O.2) Symptom Checklist-90 revised. O.3) Life stressor burden Scale. O.4) PSRS, support from friends. O.5) PSRS, support from family. O.6) Barriers to Care Scale. O.7) Social well-being. O.8) Emotional well-being. O.9) Coping Self-Efficacy Scale (all O are scores). | O.4) Significant difference between I.2 and C at four months (P<0.04) and eight months (P<0.05). O.6) Significant difference between I.2 and C at four months (P<0.05). O.1) O.2) O.3) O.5) O.7) O.8) O.9) No significant differences between I1, I2 and C. |
| Stein2007 | Two AIDS programclinics, Rhode IslandHospital, US. | Depressedpeople livingwith HIV. |
| Group onlyreceiving theoutcome assessments. | O.1) BDI mean change score. O.2) Relative BDI reduction ≥50%. O.3) Categorical BDI improvement. O.4) BDI <10. O.5) Use of psychiatric medications. O.6) Mental and physical function subscales of the Short Form-36 mean change score. | O.1) - O.6) no significant differences between I and C. |
| Ransom2008 | AIDS serviceorganisationsin ten statesof the US. | Depressedpeople livingwith HIVin ruralareas. |
| Usual carewith access toall services. | O.1) BDI mean change score. O.2) Outcomes Questionnaire (psychiatric distress). O.3) PSRS O.4) Loneliness Scale (all O are mean change scores). | O.1) I: 5.2 (pre: 28.7, SD = 11.2 and post: 23.5, SD = 12.5), C: 0.5 (pre: 26.1, SD = 10.8 and post 25.6: SD = 13.5). Significant difference between I and C (P<0.05). O.2) I: 8.5 (pre: 87.0, SD = 24.0 and post: 78.5, SD = 31.3), C: 1.5 (pre: 78.2, SD = 22.0 and post: 76.7, SD = 26.6). Significant difference between I and C (P<0.05). O.3) O.4) No significant differences between I and C. |
Abbreviations: US = United States, N = number of participants, SD = Standard deviation, BDI = Beck Depression Inventory, PSRS = Provision of Social Relations Scale.
Overview of the medication adherence and smoking cessation studies.
| Study | Setting | Participants | Intervention (I) | Control (C) | Outcomes (O) | Results |
|
| ||||||
| Collier 2005 | Substudy of AIDS Clinical Trials Group study in the US. Puerto Rico and Italy. | Antiretroviral treatmentinitiating peopleliving withHIV. |
| Usual adherence support. | O.1) Virologic failure. Time points: weeks 0, eight, 16,24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128. O.2)≥95% medication adherence. Time points: weeks 0, eight, 16, 24, 48, 72, and 96 and if participants had confirmed virologic failure. | O.1) I: 32% C: 37%. No significant difference between I and C (P = 0.32). O.2) I: 53%, C: 48% at 96 weeks. No significant difference between I and C (P = 0.46, odds ratio = 0.86, 95% confidence interval [0.57–1.29]). |
| Reynolds 2008 | Substudy of AIDS Clinical Trials Group study in five states of the US. | Antiretroviral treatmentinitiating peopleliving withHIV. |
| Usual care patient education. | O.1) Mean adherence rate. Time-points: across weeks 4 to 64. O.2) Time to virologic failure. Time-points: weeks four, eight, 12, 16, 20, and24; and every eight weeks thereafter. | O.1) I: 97.5%; SD = 4.8, C: 97.0% SD = 5.0. Significant difference between I and C (P = 0.023). O.2) No significant difference between I and C (P = 0.21). |
|
| ||||||
| Vidrine 2006 | Primary-care clinic located within a large, inner-city HIV/AIDS care centre, Houston, Texas, US. | Smoking people living with HIV, multi-ethnic and disadvantaged. |
| Recommendedusual care. | O.1) Point prevalence abstinence. O.2) Sustained abstinence. O.3) Number of quit attempts. O.4) Longest period of abstinence. | O.1) I: 29.2%, C: 8.5% (P = 0.040, odds ratio = 3.8, 95% confidence interval [1.1–13.4]). O.4) I: 24.4 days, C: 10.2 days (P = 0.023, odds ratio = 12.3, 95% confidence interval [1.7–23.0]). O.2) O.3) No significant difference between I and C. |
Abbreviations: US = United States, N = number of participants, SD = standard deviation.
Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.
Figure 2Risk of bias summary.
Blue = low risk of bias; Red = high risk of bias; Yellow = unclear risk of bias. Methodological quality summary of the risk of bias; review authors’ judgements about each methodological quality item for each included study based on published articles.